Department of Pathology, University of Pittsburgh, Pittsburgh, PA.
Adv Anat Pathol. 2014 Mar;21(2):94-9. doi: 10.1097/PAP.0000000000000012.
The rapid development of targeted therapies has tremendously changed clinical management of lung carcinoma patients and set the stage for similar developments in other tumor types. Many studies have been published in the past decade in search for the most acceptable method of assessment for predictors of response to targeted therapies in lung cancer. As a result, several guidelines for molecular testing have been published in a past couple of years. Because of accumulated evidence that targetable drugs show the best efficacy and improved progression survival rates in lung cancer patients whose tumors have a specific genotype, molecular testing for predictors of therapy response has became standard of care. Presently, testing for EGFR mutations and ALK rearrangements in lung adenocarcinoma has been standardized. The landscape of targetable genomic alterations in lung carcinoma is expanding, but none of other potentially targetable biomarkers have been standardized outside of clinical trials. This review will summarize current practice of molecular testing. Future methods in molecular testing of lung carcinoma will be briefly reviewed.
靶向治疗的迅速发展极大地改变了肺癌患者的临床管理模式，并为其他肿瘤类型的类似发展奠定了基础。在过去的十年中，已经发表了许多研究，以寻找评估肺癌靶向治疗反应预测因子的最可接受方法。因此，在过去的几年中已经发布了几项分子检测指南。由于有证据表明，在肿瘤具有特定基因型的肺癌患者中，靶向药物显示出最佳疗效和改善的进展生存率，因此针对治疗反应预测因子的分子检测已成为标准护理。目前，已经对肺腺癌中的 EGFR 突变和 ALK 重排进行了标准化检测。肺癌中可靶向的基因组改变的范围正在扩大，但除临床试验外，其他潜在的可靶向生物标志物均未标准化。这篇综述将总结目前的分子检测实践。还将简要回顾肺癌的分子检测的未来方法。
